Department of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Toxins (Basel). 2017 Dec 16;9(12):403. doi: 10.3390/toxins9120403.
Since its approval by the US Food and Drug Administration in 2002 for glabellar wrinkles, botulinum toxin (BTX) has been widely used to correct facial wrinkles. As a result, many consider BTX synonymous with cosmetic dermatology. Recent studies indicate that BTX elicits biological effects on various skin cell types via the modulation of neurotransmitter release, and it seems that BTX has a wider zone of dermatologic influence than originally understood. Clinicians and researchers are now beginning to explore the potential of BTX beyond the amelioration of facial lines and encouraging results are seen with BTX in a variety of skin conditions. In this paper, we review novel dermatological indications of BTX which includes (but not limited to) scar prevention, facial flushing, post-herpetic neuralgia and itch. These areas show great promise, but there is definite need for larger, double-blinded, randomized control trials against established treatments before BTX becomes a clinical reality.
自 2002 年美国食品和药物管理局批准用于治疗眉间皱纹以来，肉毒毒素（BTX）已被广泛用于纠正面部皱纹。因此，许多人认为 BTX 是美容皮肤科的代名词。最近的研究表明，BTX 通过调节神经递质的释放对各种皮肤细胞类型产生生物学效应，而且 BTX 的皮肤科影响范围似乎比最初理解的要广泛。临床医生和研究人员现在开始探索 BTX 在改善面部线条以外的潜在用途，并且在各种皮肤疾病中，BTX 都取得了令人鼓舞的效果。在本文中，我们综述了 BTX 的新的皮肤科适应证，包括（但不限于）瘢痕预防、面部潮红、带状疱疹后神经痛和瘙痒。这些领域显示出巨大的潜力，但在 BTX 成为临床现实之前，还需要针对已确立的治疗方法进行更大规模、双盲、随机对照试验。
